Shanghai Henlius Biotech (HKSE:02696) Total Payout Ratio : 0.00 (As of May. 29, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Shanghai Henlius Biotech's current Total Payout Ratio is 0.00.

Shanghai Henlius Biotech Total Payout Ratio Historical Data

The historical data trend for Shanghai Henlius Biotech's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Total Payout Ratio Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

Get a 7-Day Free Trial

3.37

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Payout Ratio	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Shanghai Henlius Biotech's Total Payout Ratio

For the Biotechnology subindustry, Shanghai Henlius Biotech's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Henlius Biotech's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Total Payout Ratio falls into.

Shanghai Henlius Biotech Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Shanghai Henlius Biotech's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	622.992
	=	0.00

Shanghai Henlius Biotech's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	0
	=	N/A

Shanghai Henlius Biotech Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech (HKSE:02696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you
Jiang Wei-dong	2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc.	2101 Beneficial owner

Shanghai Henlius Biotech (HKSE:02696) Headlines

No Headlines